Skip to main
STIM
STIM logo

Neuronetics Inc (STIM) Stock Forecast & Price Target

Neuronetics Inc (STIM) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neuronetics Inc. has demonstrated a notable sequential increase in capital sales, reaching $4.4 million, reflecting a strong upward trajectory in its business performance. The company has reported an 18% year-over-year increase in its local consumables segment, further supporting the operational growth and indicating robust demand for its NeuroStar Advanced Therapy System. Additionally, with improvements observed in Greenbrook sites and enhanced efficiency metrics for participating practices, Neuronetics is positioned for increased revenue growth and an accelerated path to profitability amid a strengthening balance sheet, indicating a positive outlook for its financial future.

Bears say

Neuronetics, Inc. has reported a significant decline in revenue, with NeuroStar revenues falling to $4.0 million, reflecting an 11% year-over-year decrease. The company's sales guidance for Q3 2024, projected between $18.5 million to $19.5 million, is below analysts' expectations, indicating a 6% decrease compared to prior guidance. Additionally, the impact of a cybersecurity incident has contributed to revenue shortfalls, with management citing a cash collection shortage of approximately $2 million, compounding the challenges faced by the company.

Neuronetics Inc (STIM) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neuronetics Inc (STIM) Forecast

Analysts have given Neuronetics Inc (STIM) a Buy based on their latest research and market trends.

According to 5 analysts, Neuronetics Inc (STIM) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neuronetics Inc (STIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.